In addition, Prexasertib, a checkpoint kinase 1 (CHK1) inhibitor (CHK1i), was demonstrated to induce DNA double‐strand breaks to activate STING signaling, thereby enhancing T‐cell aggregation in tumors in mice with small cell lung cancer (SCLC).369. Here, CHEK1 is linked to small cell lung carcinoma.